1. Home
  2. CHGA vs OGEN Comparison

CHGA vs OGEN Comparison

Compare CHGA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Change Agents Corporation Common Stock

CHGA

Change Agents Corporation Common Stock

N/A

Current Price

$0.22

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

N/A

Current Price

$0.54

Market Cap

2.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHGA
OGEN
Founded
N/A
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.8M
IPO Year
2015
2010

Fundamental Metrics

Financial Performance
Metric
CHGA
OGEN
Price
$0.22
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
278.7K
20.0K
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
33.18
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.48
52 Week High
$0.24
$1.45

Technical Indicators

Market Signals
Indicator
CHGA
OGEN
Relative Strength Index (RSI) 43.78 47.12
Support Level $0.18 $0.49
Resistance Level $0.23 $0.60
Average True Range (ATR) 0.02 0.03
MACD 0.00 0.00
Stochastic Oscillator 65.75 59.67

Price Performance

Historical Comparison
CHGA
OGEN

About CHGA Change Agents Corporation Common Stock

Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: